NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that results from clinical and pre-clinical studies involving two of its immunology pipeline compounds, BMS-945429 (ALD518) and BMS-582949, will be shared during five presentations at the American College of Rheumatology (ACR) Annual Scientific Meeting being held in Atlanta from November 6 to 11. The five presentations related to these early-stage compounds are in addition to 12 ORENCIA® (abatacept) abstracts covering the intravenous (I.V.) and subcutaneous formulations, which will also be presented at ACR. The presentation of these data highlights the company’s continued commitment to exploring new treatment options addressing unmet medical need for patients living with rheumatoid arthritis (RA), via different mechanisms and I.V., subcutaneous and oral routes of administration.
